<table border="single" id="id_52d45e9a-fed2-4c60-a318-d31197a8f230" width="357" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_dcd29f39-d79e-490a-a7a6-3f5773caf1ba">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="38.1%"></col>
<col width="26.6%"></col>
<col width="35.3%"></col>
<tbody>
<tr id="id_e78e5d73-6544-4443-aa18-2d0e6f7ef718">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Clinical Comment</td>
</tr>
<tr id="id_e5b87f2e-14f5-4105-9641-e05f4780d0bb">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine levels approximately 50%. </td>
</tr>
<tr id="id_25166c15-ea8f-45a4-b334-c1f962486575">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_07329b2d-4d96-48d2-be5f-8f241d20d48e">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_2749ab3b-510d-4c76-a722-fe19da51c1ff">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels. </td>
</tr>
<tr id="id_9545ba96-e2aa-472f-b6bf-618fa92c81fa">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_878ea0f3-ad2e-4e3d-bc78-8e6413c8f0d1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_e5dfebab-a012-417e-8b3f-5e525c136ca1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr id="id_f8a36e64-a150-4533-b95a-061e2716ba96">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2 fold. </td>
</tr>
<tr id="id_b3771593-a416-4049-9c13-18f4b0b4f716">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3 week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>